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Abstract 
In order to metastasize, cancer cells must first detach from the primary tumor, migrate, invade through tissues, 
and attach to a second site. Hakai was discovered as an E3 ubiquitin-ligase that mediates the posttranslational 
downregulation of E-cadherin, a major component of adherens junctions in epithelial cells that is characterized 
as a potent tumor suppressor and is modulated during various processes including epithelial–mesenchymal 
transition. Recent data have provided evidences for novel biological functional role of Hakai during tumor 
progression and other diseases. Here, we will review the knowledge that has been accumulated since Hakai 
discovery 10 years ago and its implication in human cancer disease. We will highlight the different signaling 
pathways leading to the influence on Hakai and suggest its potential usefulness as therapeutic target for cancer. 
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1. Introduction 
Most of the human common tumors are carcinomas; which arise from epithelial cells. Epithelial 
cells are connected to each other by cell–cell contacts which determine cell polarity and participate in 
cell differentiation and in the establishment and maintenance of tissue homeostasis. Cell–cell contacts 
are regulated in epithelial cells during embryonic development and in disease such as tumor 
development. For instance, the downregulation of cell–cell adhesion is a hallmark characteristic of 
epithelia–mesenchymal transitions (EMT), a process by which cells lose their polarized epithelial 
phenotype and concomitantly acquire a migratory or mesenchymal phenotype [1]. E-cadherin is the 
best characterized and prototype member of the classical cadherins in epithelial cells and is 
characterized as a potent tumor suppressor, being considered hallmark of tumor malignancy [2]. 
Epithelial tumors often lose E-cadherin partially or completely as they progress toward malignancy 
[3, 4]; and most studies have shown its anti-invasive and antimetastatic roles [5, 6]. Given the huge 
importance of E-cadherin in cancer field, it has been extensively studied the mechanisms involved on 
its inactivation in human cancers; up to date, it has been addressed several mechanisms: first, a 
genetic mechanism, such as inherited or somatic mutations; second, epigenetic mechanism, such as 
hypermethylation of E-cadherin promoter or transcriptional silencing by different repressor including 
Twist, Snail, and ZEB family members and their respective miRNA regulators; and third, E-cadherin 
can also be regulated by posttranslational modifications, such as phosphorylation, glycosylation, and 
proteolytic processing [7, 8]. In 2002, it was identified the first posttranslational regulator of E-
cadherin stability, named Hakai [9]; since then many articles have described the emerging biological 
functions for Hakai protein pointing out its influence on tumor progression and disease. Here, we will 
review the knowledge that has been accumulated since Hakai discovery 10 years ago. 
2. Hakai role at adherens junctions 
In polarized epithelia of vertebrates, adhesion between epithelial cells is mediated by distinct 
junctional complexes named tight junctions, at the apical site, adherens junctions (AJ) at the 
subapical site, and desmosomes, at basolateral site [10]; these three types of junctions are linked to 
the cytoskeletal filaments. Although all types of junctions are functionally important, it has been 
shown that AJ are crucial for the regulation of the dynamics of epithelial cell sheet and can also 
transmit intracellular signals to the interior of the cell under response of extracellular stimuli [11]. AJ 
are adhesive structures that are regulated in a Ca
2+
-dependent manner. Calcium-dependent junctions 
are constitute by a group of type-I transmembrane proteins, and its founding member was termed 
cadherin [12, 13]. Related molecules identified were also called by several names, such as 
uvomorulin [14], L-CAM [15], and A-CAM [16]. Original cadherins form a superfamily that is now 
called “classical” cadherins; however, it has been discovered other members (desmocollin, 
desmoglein, μ-protocadherin, CNR-cadherin, seven transmembrane cadherin, T-cadherin, and FAT-
family cadherins) [17]; moreover, other proteins called nectins were later identified as an AJ 
components, a family of immunoglobulin-like transmembrane proteins that function in a calcium-
independent way to promote cell–cell adhesion [18]. The classical cadherins comprises more than 20 
members that contain a common organization domain. The members are called E-cadherin (epithelial, 
Cdh1), N-cadherin (neuronal, Cdh2), P-cadherin (placental, Cdh3), and so on, each of which shows a 
distinct tissue distribution [19]. The organization domain consists of an extracellular domain and a 
cytoplasmic domain. The extracellular domain is divided into five repetitive subdomains, also called 
cadherin repeats, and every subdomain contain calcium-binding sequences [20]. On its association 
with calcium, the extracellular domain of cadherins of a cell form homophilic interactions with the 
extracellular domain of the cadherin of neighboring cell (Fig. 1a, epithelial phenotype). The 
cytoplasmic domain is highly conserved among classical cadherins and interacts with cytosolic 
proteins called catenins [21, 22, 23]. p120 and β-catenin (homologous to Drosophila melanogaster 
Armadillo) bind to the cytoplasmic tail of the cadherins, and β-catenin binds to α-catenin to form the 
cadherin–catenin complex. It has been shown that the link of cadherin to the actin cytoskeleton is 
mediated through the constant shuttling of α-catenin between cadherin/β-catenins and actin which 
may be a key to explain the dynamic aspect of cell–cell adhesion [24, 25]. Cadherin-based cell–cell 
contacts are not static but are often dynamically modulated during various physiological and 
pathological processes including mitosis, epithelial–mesenchymal transition during tumor 
progression and embryonic development. In all these processes, cadherin has been reported to be 
downregulated by endocytosis. In epithelial cells, activation of tyrosine kinases such as epidermal 
growth factor receptor (EGFR), the hepatocyte growth factor (HGF) receptor c-Met, the fibroblast 
growth factor receptor or Src, induces cell scattering and a fibroblast-like morphology [26, 27]. Met 
and Src, respectively, have an active function in this process, as they phosphorylate tyrosine residues 
in the cytoplasmic domain of E-cadherin, thereby promoting its internalization by endocytosis. Fujita 
et al. [9] underlined the molecular mechanism responsible for this internalization. A new protein 
named Hakai (which means destruction in Japanese) was identified as a responsible for the binding to 
the tyrosine phosphorylated E-cadherin mediating its internalization and subsequent ubiquitin-
dependent degradation thereby altering cell–cell contacts. In the ubiquitination process, ubiquitin 
moieties itself is involved and three different types of enzymes: the ubiquitin-activating enzyme (E1), 
the ubiquitin-conjugating enzyme (E2), and a variety of ubiquitin ligases (E3). The E3 ubiquititn 
ligases provides the specificity as they recognize the substrate through highly specific protein–protein 
interactions [28]. Hakai, also known as CBLL1, functions as an E3 ubiquitin ligase for E-cadherin 
that binds to its cytoplasmic domain after tyrosin phosphorylation by tyrosine kinase v-Src. The Src 
family plays a pivotal role in the regulation of several biological functions associated to changes in 
morphology, including malignant transformation, cell plasticity, and modulation of intercellular 
adhesion during EMT [29]. Hakai induces E2-dependent ubiquitination of the E-cadherin complex 
followed by endocytosis, disrupting cell–cell adhesions and facilitating cell motility under 
physiological conditions. Although the ubiquitination is one of the most general mechanisms to target 
cytosolic or nuclear proteins for degradation via proteasome, many membrane proteins have triggered 
degradation into lysosomes. The first work published in Saccharomyces cerevisiae demonstrated that 
Ste2p, a G protein-coupled cell surface receptor, undergone ligand-dependent ubiquitination, 
following internalization into vesicle to be finally degraded into lysosomes [30]. In fact, it has been 
shown that upon activation of Src in Madin-Darby canine kidney (MDCK) cells, intracellular E-
cadherin is shuttled to the lysosomes for degradation, instead of following normal route of the non-
ubiquitinated E-cadherin that is recycled back to the lateral plasma membrane to reform new cell–cell 
contacts [31, 32, 33]. Indeed, the modification of E-cadherin by ubiquitin is essential for its sorting to 
the lysosomes, which occurs by a process mediated by hepatocyte growth factor receptor substrate 
and the activation of specific Rab GTPases (Rab5 and Rab7). Rab5-GTP may serve to enhance the 
rate of E-cadherin transport, and Rab7 activation may serve to shift the balance to endocytic traffic 
toward the lysosomes. In consequence, cell–cell contacts do not reform and cells remain motile 
which underlined the first posttranslational mechanism to downregulate E-cadherin during EMT 
(Fig. 1b, fibroblast-like phenotype) [9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26, 27, 28, 29, 30, 31, 32, 33, 34]. 
  
 
 
 
Fig. 1. Posttranslational mechanism to donwregulate E-cadherin at AJ by Hakai. a Epithelial phenotype. E-cadherin contains 
five repetitive subdomains to conform the extracellular domain by which it forms homophilic interactions to the extracellular 
domain of the E-cadherin of the neighboring cell. Its cytoplasmic domain contains two sequences: CH2 domain that interact 
with p120-catenin and the CH3 domain interacting with β-catenin. It is also linked to the actin cytoeskeleton through the 
dynamic shuttling of α-catenin between cadherin/β-catenin and actin. b Fibroblastic-like phenotype induced by Hakai. After 
tyrosine phosphorylation by Src in the cytoplasmic domain of E-cadherin, Hakai induces the ubiquitination of the complex, 
following endocytosis into vesicles through the action of Rab5 and Rab7 to finally degrade into lysosomes, altering the 
integrity of cell–cell contacts 
Hakai protein was identified by using yeast 2-hybrid screen of an E10.5 mouse cDNA library (on 
which a bait vector containing an activated Met-kinase, trp-Met) fused to the C-terminal sequence E-
cadherin. The cytoplasmic domain of the E-cadherin contains two sequences, cadherin homology 2 
(CH2) and cadherin homology 3 (CH3) domains, conserved between classical cadherins; respectively 
[35, 36]. p120 and β-catenin can interact with these two domains, respectively; however, its 
interaction does not depend on the activation of trp-Met. Instead, Hakai interacts with the all 
cytoplasmic domain, the CH2 domain contains three closed tyrosine residues (in mouse: 756, 757, 
and 758), of which the first and second ones are specific for E-cadherin and the third one is also 
conserved between cadherins, including N and OB cadherins. Hakai was unable to interact with these 
two cadherins, neither with several tyrosine kinase receptors, suggesting that its binding is specific on 
phosphorylated E-cadherin. By the identification of the crystal structure of p120-catenin in complex 
with the fragment of cadherin it was proposed that p120 might influence the stability and function in 
cell–cell adhesion complexes [37, 38]. p120-catenin can interact to the juxtamembrane domain of E-
cadherin (including tyrosine-phosphorylation sites, where Hakai is also able to interact), therefore, it 
was believed that the binding of p120 to the juxtamembrane domain of cadherin block factors such as 
the ubiquitin-ligase Hakai and components of the endocytic machinery, which tag and target cadherin 
for destruction and internalization [9, 37, 38, 39]. It was proposed that p120 associates with cadherin 
through both “static” and “dynamic” interactions over an extended stretch of the juxtamembrane 
domain. The static interactions reflect strong interactions mediated by the highly conserved core of 
the juxtamembrane domain, and the dynamic interactions, presumably reflect interactions with lower 
affinity. These motifs in the juxtamembrane domain coincide with those linked to endocytosis by 
clathrin or Hakai-associated mechanisms [37, 38]. The binding sites for Hakai and p120 are closely 
apposed in the intracellular juxtamembrane domain of E-cadherin and, accordingly, p120 is displaced 
by the binding of Hakai to E-cadherin before endocytosis [9]. Moreover, it is well-known that p120 is 
also phosphorylated by Src kinase and receptor tyrosine kinases [40] and that acidic pH activates c-
Src [41]. An acidic extracellular pH is a feature of the tumor microenvironment and has been 
associated with tumor behavior [42, 43]. Chen et al. showed that acidic extracellular pH induced 
activation of Src and Fyn and resulting in a tyrosine phosphorylation of E-cadherin and p120 in 
HepG2 epithelial cells, which was subsequently bound to Hakai and ubiquitin. In consequence, an 
acidic pH is also weakening the association of E-cadherin and p120 and contributing to the instability 
of E-cadherin at adherens junctions [41, 44].  
3. In vivo studies of Hakai at adherens junctions 
The functional role for Hakai in vivo came out in studies carried out in D. melanogaster. Hakai is 
highly conserved in metazoans, however, in Drosophila, Hakai did not interact directly to the 
intracellular domain of Drosophila E-cadherin, suggesting not only a different mode of association 
between these proteins but also that Drosophila Hakai does not play a major and direct role in 
downregulation of E-cadherin levels [45]. As the structure of Drosophila Hakai protein predicts 
cytoplasmic localization, its interaction to Drosophila E-cadherin is likely indirect, involving at least 
components that binds the cytoplasmic Hakai protein and the extracellular or transmembrane domain 
of E-cadherin. Indeed, Hakai overexpressed was absent from cell–cell interfaces, but it localized with 
E-cadherin in cytoplasmic vesicles that are different from known endosomal compartments labeled 
with Rab5, Rab7, or Rab11. These results suggested that Hakai coexist with E-cadherin in an 
intracellular vesicle compartment that still has not been identified. Only when E-cadherin was 
coexpressed together with Hakai, they were both found enriched at cell–cell contacts sites. Moreover, 
by in situ hybridization, Hakai mRNA expression was highly detected in blastoderm stage embryos 
and transcripts persisted up to stage 14; high levels of Hakai mRNA was also detected in migrating 
endoderm cells, distributed through membranous structure in the cytoplasm, perinuclear region, and 
the plasma membrane, suggesting its possible implication in the migration of these cells over the 
visceral mesoderm. As endoderm epithelia and visceral mesoderm do not express E-cadherin, 
additional Drosophila Hakai targets need to be identified and its possible implication in cell adhesion 
and migration in endoderm and visceral development (for human Hakai substrates see below). In 
addition, a number of proteins that can interact with Drosophila Hakai were identified, underlying the 
importance of aPKC and TNF-like protein IMD (immune deficiency). In conclusion, that Hakai is 
essential for early embryonic morphogenesis was demonstrated in Drosophila, and may also be 
involved in regulating multiple target proteins that can influence epithelial development in 
Drosophila [45]. 
4. Hakai molecular structure 
E3 ubiquitin ligases contain motifs for recognizing specific substrates proteins and are key control 
points for protein ubiquitination. Up to now, the majority of the ubiquitin ligases identified can be 
divided into two categories on specific structural motifs: (A) those containing HECT domain and (B) 
those containing the RING-finger domain [46, 47]. The Cbl family ubiquitin ligase in mammals 
contains three members: c-Cbl, Cbl-b, and Cbl-c. These members are a single subunit RING-finger 
E3 containing several motifs surrounding the RING finger: a highly conserved N-terminal phosphor-
Tyr binding (pTyr-B) domain that is composed of a four-helix bundle, a calcium-binding domain 
known as “EF hand”, and an atypical SH2 (Src homology 2) domain. The pTyr-B domain mediates 
interactions between CBL proteins and the phosphorylated residues on its CBL substrates. The RING 
finger and pTyr-B domains are separated by an α-helical linker region, important for the regulation 
on its E3 ligase function. In the C-terminal region, CBL proteins have proline-rich domains that 
mediate interactions with SH3-containing proteins, and tyrosine that become phosphorylated and 
mediate interactions with SH2 proteins [28]. In eukaryotic cells, phosphorylation regulates cell 
signaling by pTyr-B domains typified by the SH2 and pTyr-B (PTB) domains. By molecular 
modeling, it was assumed that the pTyr-B domain of Hakai was a derivative SH2 domain [9], 
(Fig. 2a). Hakai contains three domains: a typical RING finger, a short pTyr-B domain, and a proline-
rich domain [9], considering that Hakai was structurally and functionally related to c-Cbl. Hakai 
contains 491 amino acids, sharing 97% homology between human and mouse sequences. The 
predicted amino acid sequence at its N-terminal contained a C3HC4-type RING finger domain, also 
present in many E3 ubiquitin ligases [48, 49], and in the C-terminal region, 35% of the amino acids 
are proline residues. However, Hakai and c-Cbl are not true homologues. A recent study has 
deepened into the molecular structure of E3 ubiquitin-ligase Hakai highlighting a novel pTyr-B 
domain [50]. This domain was named HYB (Hakai pTyr-binding) and consists of a homodimer 
formed at a structurally novel interface. Each monomer consists of two, a RING finger domain and a 
short pTyr-B domain that incorporates an atypical and novel zinc-finger coordination motif that 
incorporate connected configuration (Fig. 2b). Therefore, the HYB is constituted by four zinc-binding 
domains that participate to bind pTyr residues surrounded by acidic amino acids [50]. The previously 
described target motif was in Src-phophorylated E-cadherin, where two consecutive tyrosine residues 
(Y753 and Y754 in humans) were reported to be involved in the interaction with Hakai. They 
analyzed the contribution of these tyr residues and conclude that the phosphorylation of Y754 of the 
E-cadherin is the only tyrosine significantly involved in the binding, and also that a cluster of 
negative charges from acidic amino acids around this Y754 of E-cadherin was also important. Indeed, 
they have shown an important contribution from aspartic acid (D756) and glutamic acid (E757), and 
significant contributions from valine (V752) and aspartic acid (D750). By mass spectrometry, they 
also identified a list of novel Hakai-binding proteins phosphorylated by Src. They showed that like E-
cadherin, cortactin and DOK1 interact with Hakai only when phosphorylated by Src. Moreover, they 
suggested that this novel HYB identified was also present in other proteins such as ZNF645, a testis-
specific human E3 ubiquitin ligase [51], and possibly in Ligand-of-Numb protein X1 and 2 (LNX1 
and LXN2). Hakai and ZNF645 share significant homology, however ZNF645 bound to v-Src 
phosphorylated E-cadherin but not to cortactin, indicating that they likely have their own sets of 
targets due to differences found in their sequences between the key zinc-coordinating residues. By 
tissue distribution, they also suggest that ZNF645, found only in primates, is most likely a recent 
copy of Hakai and an intronless, indicating that is a retrotransposed copy of Hakai [50]. In 
conclusion, by combining biochemical and crystal structural analyses, authors demonstrated 
important mechanism by which E3 ubiquitin ligase Hakai binds its targets molecules. They identified 
a novel HYB domain that is present in other E3 ubiquitin ligases proteins, often deregulated in cancer 
and other disease. Therefore, it is suggested that this HYB domain can represent a specific target for 
directed therapies in cancer. 
 
 
 
Fig. 2. A schematic domain structure of c-Cbl and Hakai proteins. a Domain structure of c-Cbl protein contain a 
phophotyrosin-binding domain (pTyr-B), a RING-finger domain, a proline-rich region, and a lucine zipper (Leu-Z) domain. b 
Molecular structure of E3 ubiquitin-ligase Hakai. A novel domain, HYB (Hakai pTyr-binding) consist of a pair of monomers 
arranged in an anti-parallel configuration. Each monomer consists of two zinc-finger domains: a RING finger domain and a 
short pTyr-B domain that incorporates a novel, atypical Zn-finger coordination motif. Both domains are important for 
dimerization 
5. Hakai in response to oncogenic signaling pathways 
Although it was demonstrated that Src expression regulates ubiquitin-dependent E-cadherin 
lysosomal degradation [33], it was no until 2008 when for the first time Shen et al. reported upstream 
regulation [52]. It was previously established that Src, and non-receptor kinase, is a central regulator 
of signaling downstream of EGFR and it was also shown to regulate EMT by disrupting adherens 
junctions [53, 54]. On the other hand, Rho GTPases, including Cdc42, Rac1, and RhoA, have all been 
described to regulate adherens junctions [55, 56]. The majority of previously published data showed 
that the internalized E-cadherin induced by Ca
2+
 depletion was either recycled back to the plasma 
membrane or transiently maintained in endosomes of the cells [31, 57]. Given the roles of Cdc42, 
Src, and EGFR in adherens junction dynamics, it was studied whether they cooperatively contribute 
to the dissolution of adherens junctions, leading to E-cadherin ubiquitination and degradation. They 
demonstrated that after Ca
2+
 depletion Cdc42 was activated and in consequence it was initiated the 
activation of EGFR and Src. Activated Src, in turn, tyrosine phosphorylate E-cadherin, leading to 
Hakai-mediated E-cadherin ubiquitination. Furthermore, they reported that Cdc42 binds to E-
cadherin in a GTP-dependent manner and that this binding is essential for Cdc42 to induce the 
dissolution of adherens junctions [52] (Fig. 3a). 
 
 
 
Fig. 3. Hakai upstream signaling pathways. a Ca2+ depletion activate Cdc42 to initiate activation of EGFR and Src, which in 
turn phosphorylate E-cadherin, leading Hakai-mediated E-cadherin ubiquitination and degradation. The inhibition of Rack1 of 
the epithelial cell–cell adhesions by regulating Src and growth factor induced endocytosis of E-cadherin. b TGFβ and Raf 
signaling crosstalk to regulate EMT at posttranslational through E-cadherin ubiquitination and degradation. c Slit-Robo 
signaling induces malignant transformation during colorectal cell carcinogenesis through Hakai-mediated E-cadherin 
degradation 
On the other hand, the role of Rack1 in integrin-mediated cell adhesion is well established; 
however, the function in cell–cell adhesion through E-cadherin was not clear. RACK1 is one of a 
group of PKC-interacting proteins collectively called receptors for activated c-kinases (RACKs). It 
was also previously reported that Rack1 acts as a substrate and inhibitor of Src [58, 59, 60], 
regulating cell growth through the inhibition of Src activity at G1 and mitotic cell-cycle checkpoints 
and cell survival pathways [61, 62, 63]. Taken in consideration these premises, in 2011, it was 
addressed the effect of Rack1 on Src signaling and its function on E-cadherin-mediated cell–cell 
adhesions [64]. It was shown that Rack1 promotes cell–cell adhesion by stabilizing E-cadherin and 
catenins at cell–cell junctions and reduces invasive potential of colon carcinoma cells. Rack1 
suppresses the tyrosine phosphorylation of E-cadherin and its binding catenins, attenuating the 
downstream ubiquitination of E-cadherin, by disrupting Src–E-cadherin–Hakai interactions, and 
endocytosis of E-cadherin. In consequence, it promotes the reassembly of cell–cell contacts. 
Moreover, it was demonstrated that Rack1 also block HGF-induced cell scattering by inhibiting E-
cadherin endocytosis and junctional disassembly. Therefore, Rack1 targets both Src- and growth-
factor-dependent pathways of E-cadherin endocytosis to promote cell–cell adhesion [64], (Fig. 3a). 
  
Given the increasing recognized importance of the EMT process during cancer progression (e.g., 
from benign adenoma to metastasic carcinoma) several groups have also focused in studying the 
induction of EMT in response to different signaling pathway and its influence on the E-cadherin 
downregulation through Hakai action. It is well established that tumor growth factor β (TGFβ) 
signaling plays an important role in EMT [65]. In fact, adding TGFβ to epithelial cells in culture is a 
convenient way to induce EMT in various epithelial cells. In several epithelial models, cooperation of 
the Raf/ERK/MAPK pathways and TGFβ signaling is required for induction and maintenance of 
EMT in vitro and in vivo [66, 67]. Janda et al. have demonstrated how MAPK pathway and TGFβ 
signaling crosstalk to regulate E-cadherin expression at the initial phases of EMT [68]. They have 
shown that E-cadherin is downregulated at posttranslational level at the onset of the EMT and not at 
transcriptional level, as it happens to the majority of genes targets regulated through the cooperation 
between TGFβ and Raf. This is due to an enhanced endocytosis and lysosomal degradation induced 
by synergistic activation of both pathways. Moreover, they demonstrated that Raf and TGFβ also 
cooperate in the induction of E-cadherin monoubiquitination; this effect is explained by TGFβ-
dependent transcriptional induction of the E3 ubiquitin ligase Hakai and the Raf-dependent tyrosine 
phosphorylation of E-cadherin. Although Raf cannot directly phosphorylate E-cadherin on tyrosines, 
an increase in tyrosine phosphorylation upon Raf hyperactivation suggest that Raf/MAPK pathway 
triggers a multitude of tyrosine kinases, such as Src that may directly phosphorylate E-cadherin 
(Fig. 3b). However, they suggested that additional mechanism may exist to induce lysosomal 
degradation and/or proteolytic cleavage of E-cadherin under the cooperative action of Raf and TGFβ 
as ubiquitin tagging is not sufficient for E-cadherin degradation [68]. Taken all these publications, 
Hakai seems to be involved downstream of important signaling pathways involved during tumor 
progression and in consequence more studies are required to elucidate the emerging role for Hakai as 
a potential therapeutic target. 
6. Hakai downstream of Slit-Robo signaling 
It is well established that the Slits secreted proteins guide neuronal and leukocyte migration 
through their Roundabout (Robo) transmembrane receptors [69, 70]. Moreover, it has been reported 
that Slit proteins secreted by solid tumors binds to Robo1 expressed in vascular and lymphatic 
endothelial cells to stimulate angiogenesis and lymphangiogenesis [71, 72]. Slit2 mediates directional 
migration of glioma cells [73] and its expression is elevated in human colorectal carcinoma tissues 
and cell lines [71] and Robo1 was found upregulated in colorectal carcinoma tissues, suggesting the 
possibility of an autocrine mechanism through which colorectal carcinoma cells secrete Slit2 for 
signaling through Robo1 expressed on these same cells. Zhou et al. investigated the molecular 
mechanism of autocrine Slit-Robo signaling to induce malignant transformation during pathogenesis 
of colorectal epithelial cell carcinoma [74]. They found that the overexpression of Slit2 and Robo1, 
and also the treatment with ectopic Slit2 of Robo1-positive cells with recombinant Slit1, induced 
EMT-like phenotype, while knockdown of Robo1 or blockade of Slit2 binding to Robo1 triggered the 
mesenchymal–epithelial transition (MET)-like phenotype. Robo1-Slit2 recruited Hakai to E-cadherin 
promoting its ubiquitination and lysosomal degradation. These experimental finding provide evidence 
for induction of EMT-like phenotype through Hakai-mediated E-cadherin downregulation during 
epithelial colorectal cell carcinogenesis by autocrine Slit-Robo signaling (Fig. 3c). However, Slit-
Robo signaling did not significantly reduce E-cadherin levels through transcriptional suppression of 
E-cadherin or its known transcriptional repressors (Twist, Snail, Slug, or Zeb2). In this regard, Slit-
Robo may resemble TGFβ, HGF, Wnt/Frizzled, estrogen, bone morphogenetic proteins, and 
microRNAs for reversible epithelial to mesenchymal-like transition and cell migration. These data 
were consistent to the clinical analysis of 472 clinical cases, where metastasis human colorectal 
carcinoma tissues samples showed an increase in pan-Slit, mainly Slit2, and Robo1 expression 
compared to non-metastasic samples. Therefore, these findings also reinforce the possibility to 
investigate inhibitors of Hakai and/or Slit-Robo signaling in clinical testing for treating colorectal 
carcinoma. 
  
7. Hakai functional role independent of E-cadherin 
Other functional roles for Hakai have been addressed independently of E-cadherin protein. This 
idea came from the novel human Hakai substrates identified [45, 50] and also from the observation of 
two RNA bands of 2.5 and 4.8 Kb detected by northern blot in most mouse tissues (including testis, 
heart, brain, spleen, lung, liver, skeletal muscle, and kidney); moreover, mRNA Hakai was detected 
during developmental stages from days 7 to 17 in postnatal mice. Furthermore, Hakai protein is 
ubiquitously detected even in tissues that do not contain E-cadherin, such as endoderm epithelia or 
visceral mesoderm in Drosophila, and also in human spleen and skeletal muscle [9, 45]. Indeed, in 
2009 Figueroa et al. described polypyrimidine tract-binding protein-associated splicing factor (PSF) 
as a novel Hakai-interacting protein in cells that do not contain E-cadherin, however they did not 
obtain evidence showing that Hakai induces ubiquitination of PSF. PSF was firstly identified as an 
RNA-binding protein, but it was also shown to affect multiple cellular processes, including 
transcription, pre-mRNA processing, nuclear retention, or DNA relaxation [75, 76, 77]. By using 
cDNA arrays, they determined various specific PSF-associated mRNAs encoding proteins that are 
involved in several cancer-related processes. Hakai affected the ability of PSF to bind these mRNAs 
[78, 79]. Furthermore, in this study it is shown that Hakai is involved in the regulation of cell 
proliferation in an E-cadherin downregulation-independent manner. Hakai overexpression promotes 
proliferation of various cultured cell lines and the knockdown of Hakai significantly suppressed 
proliferation of transformed epithelial cells. Additionally, the expression of Hakai was correlated to 
the proliferation rate in hyperproliferative human tissues Hakai such as endometrium and lymph 
nodes. Two proteins were proposed to influence proliferation through Hakai: PSF and cyclin D1. 
They suggested that Hakai may regulate cell proliferation by modulating PSF activity. In Hakai-
overexpressing epithelial cells, stable knockdown of PSF partially suppressed the proliferative 
influence of Hakai overexpression. Moreover, expression of a Hakai mutant lacking the RING finger 
sequence suppressed cell proliferation, suggesting that this region of Hakai is necessary for 
promoting cell division. This Hakai mutant was able to bind PSF, indicating that Hakai’s interaction 
with PSF alone did not promote cell proliferation. The physical and functional interactions between 
PSF and the E3 ubiquitin-ligase activity of Hakai await further analysis. In another hand, PSF co-
localizes with Hakai in the nucleus, raising the possibility that Hakai could play a role in the nucleus 
through its association with PSF [78, 79]. According to the possible role of Hakai in the nucleus, later 
report shows that Hakai is a corepressor of estrogen receptor alpha (ERα) in breast cancer cells. By 
transiently transfection of Hakai, it can repress the transactivation of the ERα through the direct 
binding to the ERα and by the recruitment of coactivators such as SRC-1 and GRIP-1 (also known as 
SRC-2) [80]. Hakai overexpression in a tetracycline-induced manner decreased proliferation and 
migration of ERα-dependent breast cancer MCF-7 cells [80]. These results contrast with previously 
reported [78] on which overexpression of Hakai increased proliferation in stable cell lines epithelial 
MDCK. Therefore, Hakai may exert positive or negative control of cell proliferation in different 
physiological or pathological conditions. Like Hakai, some ubiquitin ligases are reported to function 
as transcriptional regulators such as E2 ubiquitin ligase BRCA1 that modulate ERα transactivation 
[81], or RING finger LIM domain-interacting protein that enhanced the activation on targets genes 
mediated by ERα while it inhibits transcriptional activity of LIM-HD [82]. Therefore, Hakai was 
proposed as corepressor of ERα playing a role in the development and progression of breast cancer 
cells. It is possible that the proline-rich domain at the C-terminus of Hakai could be the responsible 
domain for the repression activity, as this domain is commonly contained in repression domains or 
near to them, as evidenced in p53 [83], Groucho [84], and HNF4 [85]. As it was previously reported 
for other E3 ubiquitin ligases [86], these findings suggest that Hakai can have ubiquitin-independent 
functions in the nucleus or in the cytoplasm that may influence the cell phenotype, in addition to its 
influence on known substrates (like E-cadherin) or other Hakai interacting proteins. 
  
8. Hakai and cancer: clinical applications 
There are several lines of evidence that supported a multiple function of Hakai in tumorigenesis. 
Firstly, it was reported that Hakai induced anchorage-independent cell growth; moreover, Hakai is 
highly upregulated in human colon and gastric adenocarcinomas compared to normal tissues [78]. 
New investigations found a low expression of Hakai and E-cadherin or an inverse correlation 
between both proteins, while comparing several colon adenocarcinomas although the meaning of 
these results has to be further investigated [87]. Secondly, in epithelial cells expressing E-cadherin 
shRNA do not extend spiky protrusions that are seen in Hakai-overexpressing cells [88], suggesting 
that Hakai can also affect cellular phenotypes in an E-cadherin-independent manner. Hakai is 
localized at the end of the protrusion where FAK, focal adhesion kinase, is also enriched in Hakai-
overexpressing MDCK cells, suggesting that Hakai may be involved in regulating the dynamic 
extension and retraction of these structures and in influencing cell motility [78]. Hakai’s influence on 
cell attachment to the substrate and invasion capacity of epithelial MDCK cells was addressed [89]. 
In this system, Hakai overexpression leads to a reduction in cell adhesion to the substrate with impact 
on decreasing protein levels of Paxillin, a key focal adhesion-associated protein, although its 
downregulation was controlled by a proteasome-independent mechanism [89]. Nevertheless, further 
investigations of Hakai in in vitro and in vivo model systems would lead us to validate its role during 
tumorigenesis. 
 
Taking together the previous published reports of Hakai during tumor progression, it is 
increasingly apparent that further investigations of its physiological and pathological functional role 
would lead us to a novel molecular target for cancer treatment. Up to now, there is only one reported 
publication on which it is studied the molecular mechanism involving Hakai under the action of an 
agent against cancer metastasis. One emerging approach in cancer management is the use of 
“nutraceuticals”, which are relatively nontoxic, cost-effective, and physiologically bioavailable 
component. Silibinin, a flavonoid from milk thistle seed extract, is a widely consumed dietary 
supplement that shows a strong efficacy both in vitro and in vivo against prostate cancer, establishing 
also its implication on epithelial–mesenchymal transition [90, 91, 92]. Despite the previous finding 
describing the role of silibinin, the main molecular targets responsible for its strong antimigratory and 
anti-invasive efficacy remained inconclusive. A recent study demonstrated that silibinin inhibits 
invasive and migratory potential of several highly metastasic cell lines at nontoxic concentrations. 
Under these conditions, an increased E-cadherin expression at cellular membrane and an inhibition of 
nuclear β-catenin level was found, accompanied to a decreased level of Hakai, phospho Src (tyr419), 
Slug Snail, and phosphor-Akt (ser
473
) levels, proposing these proteins as a molecular targets 
implicated in the antimigratory and anti-invasive efficacy of silibinin in prostate cancer cells [93]. 
These findings have an important translational relevance as the concentration of silibinin used in 
these studies are within the range of free silibinin levels achieved in the plasma of pancreatic cancer 
patients in a reported phase I clinical trial [94]. 
9. Other Hakai clinical applications 
Apart from the revised functional role of Hakai in cancer, it is also important to mention Hakai 
importance in other cellular processes and diseases. In a microarray profiling Hakai was found 
differentially expressed during erythroid differentiation of murine erythroleukemia cells, suggesting 
the possibility of considering Hakai as a marker for erythropoiesis [95]. Moreover, Hakai was also 
proposed to be used to evaluate the mechanism of action of immunosuppressive chemicals on which 
Hakai expression could be novel gene marker for immunosuppression in mouse lymph node assay 
[96]. More importantly, there are several reported publications that describe Hakai role in infectious 
disease. The first work describing Hakai in this process was by Krishnan et al. [97]. By using a 
human genome-wide RNAi screen they identified Hakai as a protein that affect West Nile virus 
(WNV) infection. WNV is a type of virus known as flavivirus that constitute a significant global 
human health problem [98]. They identified 20 ubiquitination-related proteins involved and they 
proposed Hakai to be involved in the cellular internalization of WNV. They demonstrated that Hakai 
and the proteasome–ubiquitin system are required for the cellular internalization of WNV [97]. This 
idea was controversial as later report did not support this data suggesting that Hakai is dispensable for 
cellular internalization during flavivirus entry [99], and that the apparent role of Hakai in WNV 
infection proposed by Krishnan et al. [97] could reflect an off-target effect produced by the RNA 
intereference screen used. They rather support a critical role of the ubiquitin/proteasome system 
during a post-entry step of the WNV life cycle, and that the proteasome activity is required for 
amplification of several flavivirus genome [99]. Still, the implication of Hakai during WNV 
infectious needs to be clarified. Other important studies on Hakai in infectious disease were reported 
in Listeria monocytogenes. Upon infection Listeria leads to a wide range of symptoms associated to 
listeriosis, such as gastroenteritis, fetoplacental, and central nervous system infections [100]. 
Internalization of L. monocytogenes with non-phagocytic cells mainly occurs via two bacterial 
surface proteins: internalin-A (InIA) and internalin-B (InIB) that has E-cadherin and Met as their 
respective major host-cell surface receptors [101, 102]. InIA interaction with E-cadherin activates β- 
and α-catenin-mediated signaling pathways involved in the formation of adherens junctions. The 
initial signals triggered by the interaction of InIA with E-cadherin enhances the internalization of E-
cadherin by Src-mediated tyrosine phosphorylation of E-cadherin followed by its ubiquitination by 
ubiquitin-ligase Hakai [103]. These posttranslational modifications also occur during bacterial 
infections and are necessary for an efficient InIA-mediated bacterial internalization which it was 
shown to be dependent on both caveolin and clathrin. All these data document not only how the 
endocytosis machinery is recruited and involved in the internalization of L. monocytogenes but also 
suggest a functional link between E-cadherin endocytosis and the formation of adherens junctions in 
epithelial cells [103]. 
10. Conclusions 
Taking in consideration the last 10 years of knowledge regarding Hakai, the acquired importance 
of this protein in cancer and other diseases is increasing apparent. All these reports point out the need 
to further investigate more deeply the molecular mechanism by which Hakai mediates its action on 
tumor progression, not only by its influence on EMT though E-cadherin downregulation but also by 
its influence on early stages of tumor formation. Moreover, novel human substrates in the nucleus or 
in the cytoplasm for Hakai need to be identified to clarify its influence on cell phenotype, including 
cell-substrate and invasion capability in tumor cells. Also, more investigations need to address the 
apparent relevance of Hakai ubiquitin-independent functions that may influence on the cell 
phenotype. Therefore, Hakai can have different functional roles in different physiological or 
pathological conditions; in consequence, it is also important to highlight the influence of different 
signaling pathways on Hakai and to investigate its clinical potential usefulness as therapeutic target 
for cancer. 
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